Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial
Glue P, Loo C, Fam J, Lane HY, Young AH, Surman P, Glozier N, Fitzgerald P, Liu D, Sharma S, et al.
Nature Medicine · 2024
Key finding
The safety and tolerability of racemic ketamine may be improved if given orally, as an extended-release tablet (R-107), compared with other routes of administration.
- Condition
- Depression
- Stimulation
- taVNS
- Evidence tier
- Randomised Controlled Trial
- Participants
- 329
Cite this study
Glue, P., Loo, C., Fam, J., Lane, H. Y., Young, A. H., Surman, P., Glozier, N., Fitzgerald, P., Liu, D., Sharma, S., Grunfeld, J., Barton, D., Hopwood, M., Miles, W., Williams, M., Carson, S., Fam, J., Tor, P. C., Lane, H. Y., … Huang, Y. J. (2024). Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial. Nature Medicine, 30(7), 2004-2009. https://doi.org/10.1038/s41591-024-03063-x
Related studies in Depression
Long-term efficacy and safety of vagus nerve stimulation in treatment-resistant depression: A systematic review
Rosson et al. · Journal of Affective Disorders · 2026 · Systematic Review / Meta-Analysis
The efficacy and safety of transcutaneous auricular vagus nerve stimulation in the treatment of depressive disorder: a systematic review and meta-analysis of randomized controlled trials
Tan et al. · Journal of Affective Disorders · 2023 · Systematic Review / Meta-Analysis
Adjunctive Vagus Nerve Stimulation for Treatment-Resistant Depression: a Quantitative Analysis
Zhang et al. · The Psychiatric quarterly · 2020 · Systematic Review / Meta-Analysis
Vagus Nerve Stimulation for Depression: A Systematic Review
Lv et al. · Frontiers in psychology · 2019 · Systematic Review / Meta-Analysis
Summary by Vagus Research. Always consult the primary source for the authoritative record.